Altimmune (0A4C) Stock Overview

A late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. More details

0A4C fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Shares are highly illiquid

Earnings are forecast to decline by an average of 14.3% per year for the next 3 years

Makes less than USD$1m in revenue ($31K)

+ 1 more risk

0A4C Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW444,721 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

444,721 investors already sharing narratives

View all narratives

Altimmune, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Altimmune
Historical stock prices
Current Share Price	US$2.89
52 Week High	US$5.87
52 Week Low	US$2.89
Beta	0.17
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	9.51%
5 Year Change	-82.25%
Change since IPO	-78.27%

Recent updates

Shareholder Returns

	0A4C	GB Biotechs	GB Market
7D	0%	-3.1%	-1.5%
1Y	n/a	-22.9%	15.5%

Return vs Industry: Insufficient data to determine how 0A4C performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how 0A4C performed against the UK Market.

Price Volatility

Is 0A4C's price volatile compared to industry and market?
0A4C volatility
0A4C Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.3%
Market Average Movement	4.9%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0A4C's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine 0A4C's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1997	57	Jerry Durso	altimmune.com

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Altimmune, Inc. Fundamentals Summary

How do Altimmune's earnings and revenue compare to its market cap?
0A4C fundamental statistics
Market cap	US$604.95m
Earnings (TTM)	-US$91.76m
Revenue (TTM)	US$31.00k

Over9,999x

P/S Ratio

-6.6x

P/E Ratio

Is 0A4C overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0A4C income statement (TTM)
Revenue	US$31.00k
Cost of Revenue	US$66.72m
Gross Profit	-US$66.69m
Other Expenses	US$25.07m
Earnings	-US$91.76m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-0.47
Gross Margin	-215,138.71%
Net Profit Margin	-296,000.00%
Debt/Equity Ratio	7.3%

How did 0A4C perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/08/31 12:48
End of Day Share Price	2026/06/03 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Altimmune, Inc. is covered by 19 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Eliana Merle	Barclays
"Eliana Merle	Barclays
Mayank Mamtani	B. Riley Securities, Inc.

Altimmune (0A4C) Stock Overview

Risk Analysis

Join community and earn perks

Altimmune, Inc. Competitors

Avacta Group

PureTech Health

Oxford Biomedica

Genus

Price History & Performance

Recent News & Updates

Altimmune, Inc. to Report Q2, 2026 Results on Aug 12, 2026

Altimmune Announces Positive Topline Results from Reclaim Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell Microcap Growth Benchmark Index

New major risk - Revenue and earnings growth

Altimmune, Inc. to Report Q1, 2026 Results on May 13, 2026

Altimmune, Inc. has completed a Follow-on Equity Offering in the amount of $224.98925 million.

Recent updates

Altimmune, Inc. to Report Q2, 2026 Results on Aug 12, 2026

Altimmune Announces Positive Topline Results from Reclaim Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell Microcap Growth Benchmark Index

New major risk - Revenue and earnings growth

Altimmune, Inc. to Report Q1, 2026 Results on May 13, 2026

Altimmune, Inc. has completed a Follow-on Equity Offering in the amount of $224.98925 million.

Altimmune, Inc. has filed a Follow-on Equity Offering.

Altimmune, Inc. to Report Q4, 2025 Results on Mar 05, 2026

Altimmune, Inc., Annual General Meeting, Apr 16, 2026

Altimmune, Inc. has completed a Follow-on Equity Offering in the amount of $74.99535 million.

Forecast to breakeven in 2028

Altimmune, Inc. has filed a Follow-on Equity Offering in the amount of $74.99535 million.

Forecast to breakeven in 2028

Altimmune, Inc. Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH

Altimmune, Inc. Announces Positive Topline Results from the Impact Phase 2B Mash Trial

Altimmune, Inc. Announces CEO Changes

Altimmune, Inc. Announces Publication of Impact Phase 2B Trial Data in the Lancet and Concurrent Late-Breaking Oral Presentation At Aasld the Liver Meeting®? 2025

Third quarter 2025 earnings released: US$0.21 loss per share (vs US$0.32 loss in 3Q 2024)

Altimmune, Inc. Presents Ai-Based Analysis of Liver Fibrosis Reduction from Impact Phase 2B Trial of Pemvidutide Inash in Late-Breaking Poster At Aasld the Liver Meeting®? 2025

Altimmune, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Altimmune, Inc. Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

Altimmune, Inc. to Report Q3, 2025 Results on Nov 06, 2025

Altimmune, Inc. Announces the Appointment of Christophe Arbet-Engels as Chief Medical Officer, Effective October 1, 2025

Altimmune, Inc. Appoints Linda M. Richardson to the Role of Chief Commercial Officer, Effective September 16, 2025

Altimmune, Inc. Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Altimmune, Inc., Annual General Meeting, Sep 25, 2025

First half 2025 earnings released: US$0.53 loss per share (vs US$0.69 loss in 1H 2024)

Holzer & Holzer, Llc Files Shareholder Class Action Lawsuit Against Altimmune, Inc

Altimmune Appoints Jerry Durso as Chairman, Effective August 12, 2025

Levi & Korsinsky, LLP Announces Filing of Class Action Against Altimmune, Inc

Altimmune, Inc. to Report Q2, 2025 Results on Aug 12, 2025

Altimmune, Inc. Announces Initiation of Restore Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease

Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 3000E Value Index

Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH

High number of new directors

Altimmune, Inc. Announces Initiation of RECLAIM Phase 2 Trial Evaluating Efficacy and Safety of Pemvidutide in Alcohol Use Disorder

Altimmune, Inc. announced that it expects to receive $100 million in funding from Hercules Capital, Inc.

Altimmune, Inc. to Report Q1, 2025 Results on May 13, 2025

High number of new directors

Altimmune, Inc. Announces Retirement of Scott Harris as Chief Medical Officer, Effective February 28, 2026

High number of new directors

Altimmune, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Altimmune, Inc. Announces Board Appointments

Altimmune, Inc. to Report Q4, 2024 Results on Feb 27, 2025

New major risk - Shareholder dilution

Altimmune, Inc. Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease at The Liver Meeting 2024

Third quarter 2024 earnings released: US$0.32 loss per share (vs US$0.39 loss in 3Q 2023)

New major risk - Revenue and earnings growth

Altimmune, Inc. Appoints Greg Weaver as Chief Financial Officer

Altimmune, Inc. Announces Successful Completion of End-of-Phase 2 Meeting with FDS for Pemvidutide in the Treatment of Obesity

Altimmune, Inc. to Report Q3, 2024 Results on Nov 12, 2024

High number of new directors

High number of new directors

Altimmune, Inc. Completes Enrollment in Phase 2B Impact Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (Mash)

Altimmune, Inc., Annual General Meeting, Sep 26, 2024

New major risk - Revenue and earnings growth

First half 2024 earnings released: US$0.69 loss per share (vs US$0.72 loss in 1H 2023)

New major risk - Revenue and earnings growth

Altimmune, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Altimmune, Inc. Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology

Altimmune, Inc. Announces Demise of Richard Eisenstadt, Chief Financial Officer

Altimmune, Inc. Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity at the American Diabetes Association’s 84th Scientific Sessions

Altimmune, Inc. Presents Data at EASL International Liver Congress™? 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)